The Marston’s share price has jumped! Should I buy the stock?

The Marston’s share price has recovered significantly in recent weeks. But the company will continue to face some significant challenges, believes Rupert Hargreaves.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Over the past 30 days, the Marston’s (LON: MARS) share price has jumped in value by more than 15%. This has helped the stock regain some of its losses over the past year. Since the middle of February 2020, the stock is down 13%

After this performance, shares in the pubs and restaurants operator are well on the way to recovering the majority of the losses suffered in 2021. As such, I’m wondering if it’s worth buying the shares today ahead of future gains. 

The outlook for the Marston’s share price 

Past performance should never be used as a guide to future potential. Just because shares in the hospitality/leisure operator have recovered some losses over the past few weeks, doesn’t mean the stock will continue to trend higher. Another wave of bad news could cause the Marston’s share price to plunge once again. 

Whenever I consider an investment for my portfolio, the first thing I do is try to understand why the stock has acted in the way it has over the previous 12 months.

With Marston’s, it’s pretty straightforward. Since March last year, rolling lockdowns have decimated the company’s revenues. The firm’s 2020 financial year revenues fell to £821m from £1.2bn in the prior period. The group lost a staggering £400m in its latest financial year, including impairment charges. For some comparison, the organisation’s current market capitalisation is £588m. 

These losses raised some serious questions about the group’s financial position. Analysts began to speculate whether the business could remain solvent and outlast the pandemic. 

Two things have changed in the past few months that have altered this view. First of all, the group received a buyout offer from US private equity firm Platinum Equity Advisors. The potential acquirer offered a price of 88p, followed by 95p, and then a final bid of 105p. Management rejected all of these attempts. However, I think they showed other investors believe there’s value in the Marston’s share price. 

The other factor that implies the company’s outlook has improved over the past six months is the completion of a transformational agreement with Carlsberg. This provided an immediate cash infusion of £233m. As well as bank facilities of £176m, the group now has plenty of cash to meet estimated outgoings of £3m-£4m per week in a full lockdown

Recovery play

All the above suggests to me the outlook for the Marston’s share price has improved dramatically over the past six months. Unfortunately, the company isn’t out of the woods just yet. Its future depends on the government’s ability to control the pandemic, which is totally out of its control. That makes the business difficult for me to value. 

Therefore, while the leisure group could be an excellent way to play the economic recovery over the next few years, I’m not going to buy the stock today. I feel there’s just too much uncertainty surrounding its future and there may be other companies (with more substantial balance sheets) better placed to capitalise on reopening trade.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended Marstons. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »